ESE-N -0.86 CPB-N -0.01 CNR-T 0.3 BIP.UN-T -0.47 GOOG-Q -6.25 DSG-T -0.72 MCY-N 1.27
Daily Stock Opinions and Ratings
Stockchase Opinions

John Sinkins, CFA Novelion NVLN-T BUY Aug 29, 2001

Will perform with biotech sector. Long term will do very well.
John Sinkins, CFAJohn Sinkins, CFA
Unknown
Unlock Rating
$30.990

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Novelion(NVLN-T)

Apr 11, 2005
This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away.
Ron MeiselsRon Meisels
No
Unlock Rating
$15.370

Stock price when the opinion was issued

biotechnology pharmaceutical
SELL

Novelion(NVLN-T)

May 25, 2005
Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in.
Norman LevineNorman Levine
No
Unlock Rating
$13.020

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Novelion(NVLN-T)

Jun 06, 2005
A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition.
Norman LevineNorman Levine
No
Unlock Rating
$12.590

Stock price when the opinion was issued

biotechnology pharmaceutical
WAIT

Novelion(NVLN-T)

Jun 15, 2005
Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through.
David CockfieldDavid Cockfield
Owned
Unlock Rating
$11.890

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Novelion(NVLN-T)

Aug 11, 2005
Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away.
Gordon Higgins, CA, MBAGordon Higgins, CA, MBA
No
Unlock Rating
$10.000

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Novelion(NVLN-T)

Sep 29, 2005
The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen.
John ZechnerJohn Zechner
No
Unlock Rating
$9.000

Stock price when the opinion was issued

biotechnology pharmaceutical
SELL

Novelion(NVLN-T)

Nov 11, 2005
The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here.
David BurrowsDavid Burrows
No
Unlock Rating
$8.100

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Novelion(NVLN-T)

Dec 22, 2005
Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent.
Laura WallaceLaura Wallace
No
Unlock Rating
$7.040

Stock price when the opinion was issued

biotechnology pharmaceutical
SELL

Novelion(NVLN-T)

Oct 23, 2007
The future isn't bright. Losing market share with their main product. Suggests tax loss selling.
David BaskinDavid Baskin
No
Unlock Rating
$4.350

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY ON WEAKNESS

Novelion(NVLN-T)

Aug 07, 2009
(Market Call Minute.) Could see it as a Buy but would like it at a cheaper price.
Benj GallanderBenj Gallander
Unknown
Unlock Rating
$4.100

Stock price when the opinion was issued

biotechnology pharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MEQ-T -1.11$188.04
NFLX-Q 9.12$1231.41
GXO-N 5.19$47.97
DIS-N -0.23$117.63
KMX-N 4.24$68.57

Today's Top Picks

ESE-N -0.86$181.45
CPB-N -0.01$31.84
CNR-T 0.3$140.05
BIP.UN… -0.47$44.76
GOOG-Q -6.25$167.73

Popular Articles

Latest Sell Signals

BRK.B-… -0.29$484.85
ACN-N -21.01$285.37
SES-T -0.07$15.02
BCE-T -0.1$29.83
T-T 0.12$21.98

Most Recent Experts

Jeff Parent B. Eng. FCSI CIM

Jeff Parent B. Eng. FCSI CIM

Castlemoore Inc.

Stockchase Insights

Stockchase Insights

5i Research

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Josh Brown, CEO, Ritholtz Wealth Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica